SV Health Investors News and Activities

SV Health Investors has a direct presence in 2 countries.

View the org chart displaying its 66 main executives

Most searched biographies at SV Health Investors

• Eugene Hill, Chairman of the Board
• Paul LaViolette, Managing Partner, Medical Technology and Chief Op...
• Greg Madden, Managing Partner, Medtech and Healthcare Growth

Popular executive movements at SV Health Investors

• Miles Gerson has joined the company as Partner, Therapeutics  (posted on March 24 2026).

Create your alert
to follow the executive moves at SV Health Investors.

SV Health Investors has 1,643 competitors including Griffin Gaming Partners (United States (USA)), BlackRock (United States (USA)) and KKR (United States (USA)).

Popular M&A news in Fund

• Bridgepoint has announced the acquisition of Obagi Medical Products  (posted on June 4 2026).
• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (posted on June 3 2026).
• Prime Capital Financial has acquired Access Capital Partners (posted on June 2 2026).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director at Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director at General Catalyst Partners

Learn more about the Fund industry

Press releases by SV Health Investors

• Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial - SV Health Investors
• Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer - SV Health Investors
• Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research - SV Health Investors
• AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid - SV Health Investors
• AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial - SV Health Investors
• Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update - SV Health Investors
• News - SV Health Investors
• SV Health Investors Acquires EpiVax - SV Health Investors
• Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS - SV Health Investors
• Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic - SV Health Investors
• View more press releases Close

Social media about SV Health Investors

• SV Health Investors on Wikipedia, Google News & Yahoo Finance
• SV Health Investors on LinkedIn, X (Twitter) & YouTube